Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical hydrocortisone for dry eye disease associated with meibomian gland dysfunction
2024-518093-13-00Phase 4Completed
- Sponsor
- Laboratoires Théa
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of hydrocortisone in dry eye syndrome (DED) and meibomian gland dysfunction (MGD), sponsored by Laboratoires Théa. Primary endpoints: Change in MGD-DE symptom score from baseline to Day 14, Change in inflammatory cytokine levels in tears from baseline to Day 14 and 1 more. Started Oct 2024; status: completed.
02
Drugs
hydrocortisone
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on 2024-518093-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518093-13-00.